Sellas Life Sciences is trading 5.8% up at $9.04; no new company announcement was identified to explain the November 3 rebound. - The stock fell to $8.55 on November 2. - Recent coverage describes investors positioning ahead of preliminary REGAL trial results expected this quarter. - Some investment firms increased third-quarter holdings; neither factor establishes the cause of today’s rise.